Evidence map›Paper›PMID 28515927›Full record

ArticleMolecular and clinical oncology2017

Body mass index as a classifier to predict biochemical recurrence after radical prostatectomy in patients with lower prostate-specific antigen levels.

Keisuke Goto, Hirotaka Nagamatsu, Jun Teishima, Yuki Kohada, Shinsuke Fujii, Yoshimasa Kurimura, Koji Mita, Masanobu Shigeta, Satoshi Maruyama, Yoji Inoue and 2 more

Open access · diamondAbstract read
In one paragraph

Article in Molecular and clinical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Keisuke GotoDepartment of Urology, Hiroshima University Institute of Biomedical and Health Sciences, Hiroshima 734-8551, Japan.
Hirotaka NagamatsuDepartment of Urology, Hiroshima University Institute of Biomedical and Health Sciences, Hiroshima 734-8551, Japan.
Jun TeishimaDepartment of Urology, Hiroshima University Institute of Biomedical and Health Sciences, Hiroshima 734-8551, Japan.
Yuki KohadaDepartment of Urology, Hiroshima University Institute of Biomedical and Health Sciences, Hiroshima 734-8551, Japan.
Shinsuke FujiiDepartment of Urology, Hiroshima University Institute of Biomedical and Health Sciences, Hiroshima 734-8551, Japan.
Yoshimasa KurimuraDepartment of Urology, Hiroshima University Institute of Biomedical and Health Sciences, Hiroshima 734-8551, Japan.
Koji MitaDepartment of Urology, Hiroshima City Asa Hospital, Hiroshima 731-0293, Japan.
Masanobu ShigetaDepartment of Urology, Kure Medical Center, Chugoku Cancer Center, Kure, Hiroshima 737-0023, Japan.
Satoshi MaruyamaDepartment of Urology, Hiroshima General Hospital, Hatsukaichi, Hiroshima 738-8503, Japan.
Yoji InoueDepartment of Urology, Mazda Hospital, Fuchu, Hiroshima 735-8585, Japan.
Mitsuru NakaharaDepartment of Urology, Hiroshima Prefectural Hospital, Hiroshima 734-8530, Japan.
Akio MatsubaraDepartment of Urology, Hiroshima University Institute of Biomedical and Health Sciences, Hiroshima 734-8551, Japan.
Hiroshima University · JPHiroshima City Asa Citizens Hospital · JPHiroshima General Hospital · JPHiroshima Prefectural Hospital · JPKure Medical Center · JPMazda Motor Corporation (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer, one of the most common malignant tumors among men, is closely associated with obesity and, thus far, several studies have suggested the association between obesity and aggressive pathological characteristics in the United States. However, the effect of obesity on prostate cancer mortality is controversial, and it remains unclear whether obesity contributes to the aggressiveness of prostate cancer in Asian patients. The aim of the present study was to investigate the association between body mass index (BMI) and the clinicopathological characteristics of prostate cancer in 2,003 Japanese patients who underwent radical prostatectomy. There was a significant association between higher BMI and higher Gleason score (GS). The multivariate analysis also revealed that BMI was an independent indicator for GS ≥8 at surgery. Moreover, among patients with lower prostate-specific antigen levels, biochemical recurrence-free survival was significantly worse in those with higher BMI. These results suggest that BMI may be a classifier for predicting adverse pathological findings and biochemical recurrence after radical prostatectomy in Japanese patients.

Indexed as

body mass indexobesityprostate cancerprostatectomyprostate-specific antigen

Identifiers

PMID28515927
PMCPMC5431309
OpenAlexW2607458785

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.